Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
Date: July 29, 2019
Issue #:
1577Summary:
The FDA has approved bremelanotide (Vyleesi– Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide is not approved for use in men or
postmenopausal women. It is the second drug to
be approved in the US for this indication; flibanserin(Addyi), which was approved in 2015, was the first.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Addyi bremelanotide female sexual dysfunction flibanserin Vyleesi Source Type: research